Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Accesswire 7 days ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Accesswire 8 days ago

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Accesswire 10 days ago

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis

Accesswire 11 days ago

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Accesswire November 7, 2024

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Accesswire November 5, 2024

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Accesswire October 29, 2024

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Accesswire September 3, 2024

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Accesswire August 6, 2024

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Accesswire August 1, 2024

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Accesswire August 1, 2024

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Accesswire July 31, 2024

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Accesswire July 22, 2024

Protagonist Therapeutics Set to Join S&P SmallCap 600

PR Newswire June 27, 2024

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

Accesswire June 14, 2024

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Accesswire May 31, 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Accesswire May 14, 2024

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

Accesswire May 7, 2024

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Accesswire May 7, 2024

Turnstone Biologics Appoints William Waddill to its Board of Directors

GlobeNewswire April 16, 2024